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Transcriptionc-Myc is upregulated in response to growth factors and transmits the signal to proliferate by altering the gene
expression landscape.When genetic alterations result in growth factor-independent c-Myc expression, it can be-
come an oncogene. Themajority of human tumour types exhibit a degree of c-Myc deregulation, resulting in un-
restrained cell proliferation. c-Myc binds proximal to the promoter region of genes and recruits co-factors
including histone acetyltransferases and RNA pol II kinases, which promote transcription. c-Myc also promotes
formation of the cap structure at the 5′ end ofmRNA. The cap is 7-methylguanosine linked to theﬁrst transcribed
nucleotide of RNA pol II transcripts via a 5′ to 5′ triphosphate bridge. The cap is added to the ﬁrst transcribed nucle-
otide by the capping enzymes, RNGTT and RNMT–RAM. During the early stages of transcription, the capping en-
zymes are recruited to RNA pol II phosphorylated on Serine-5 of the C-terminal domain. The mRNA cap protects
transcripts from degradation during transcription and recruits factors which promote RNA processing including,
splicing, export and translation initiation. The proportion of transcriptswith a cap structure is increased by elevating
c-Myc expression, resulting in increased rates of translation. c-Myc promotes capping bypromoting RNApol II phos-
phorylation and by upregulating the enzyme SAHH which neutralises the inhibitory bi-product of methylation re-
actions, SAH. c-Myc-induced capping is required for c-Myc-dependent gene expression and cell proliferation.
Targeting capping may represent a new therapeutic opportunity to inhibit c-Myc function in tumours. This article
is part of a Special Issue entitled: Myc proteins in cell biology and pathology.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
c-Myc is a potent cellular protein which is required for cell prolifera-
tion throughout development and in adult [1,2]. It is upregulated in re-
sponse to growth factors and transmits the signal for proliferation by
regulating gene expression. c-Myc is also a prevalent oncogene which is
deregulated to some extent inmost human tumour types, resulting in ab-
errant cell proliferation [1,2]. In recent years,many promising approaches
to targeting c-Myc expression or function have been discovered, and
many of these have exhibited promising results in mouse cancer models
[3]. However, currently there are no therapeutic approaches in the clinic
which speciﬁcally target c-Myc and therefore the need remains to under-
stand the molecular mechanisms by which c-Myc functions. This review
discusses the mechanisms by which c-Myc promotes mRNA cap forma-
tion, how this inﬂuences gene expression, and theopportunities for inves-
tigating capping as a therapeutic target to inhibit Myc function.
2. Discovery of c-Myc
In humans, the Myc family of proteins consists of c-Myc, N-Myc and
L-Myc. c-Myc is believed to be expressed in all proliferating cells and isc proteins in cell biology and
ing).the Myc protein most commonly deregulated in tumours. Prior to the
discovery of the mammalian Myc proteins, v-Myc was identiﬁed as
one of the ﬁrst-discovered viral oncogenes [4]. Subsequently, a cellular
homologue of v-Myc, c-Myc, was identiﬁed as a nuclear protein.
c-Myc (and all Myc proteins) were found to contain basic-helix–loop-
helix leucine zipper motifs, which had been previously observed in
sequence-speciﬁc DNA-binding proteins [5]. As a consequence of
these observations, c-Myc was conﬁrmed to be a transcription factor
which regulates protein-encoding genes, resulting in regulation of
mRNA expression in a gene-speciﬁc manner. When puriﬁed from cell
extracts, c-Myc is isolated as a heterodimer with a basic-helix–loop-
helix leucine zipper protein, Max. Max is required for c-Myc to bind to
DNA and regulates transcription [6,7]. The N-terminus of c-Myc binds
to co-factors, including histone acetyltransferases and RNA pol II
kinases, which mediate transcriptional activation and repression [2,8].
The complex details of how c-Myc regulates transcription are tackled
elsewhere in this special issue.
3. c-Myc is a transcriptional regulator
Our understanding of c-Myc as a transcription factor has evolved
with and contributed to our understanding of mammalian transcrip-
tional mechanisms. Initially c-Myc was identiﬁed as a transcription fac-
tor that increased and decreased expression of certain protein encoding
genes. The advent of micro arrays allowed “whole genome” analysis for
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lineage, c-Myc regulates transcription of approximately 10% genome,
and represses and activates genes by equivalent measure [1,8]. c-Myc
was also observed to be a relatively weak transcriptional regulator, typ-
ically activating and repressing genes by 1.5–2-fold. In the 1990s, the
ﬁrst evidence came that c-Myc regulates transcription elongation [9,
10]. Subsequently, most mammalian genes were found to have a pool
of RNA pol II paused downstream of the promoter. Release of paused
RNA pol II into elongation phase was recognised to be a rate-limiting
step in transcription [11,12]. The mechanism of RNA polymerase II
pausing and release is complex and major discoveries continue to be
made concerning the mechanism and its regulation. Recognition that
c-Myc has a pleiotropic effect on gene expression began with the dis-
coveries that c-Myc globally upregulates chromatin acetylation and
methylation associated with transcription, and that c-Myc globally in-
creases RNA pol II C-terminal domain Serine-2 and Serine-5 phosphor-
ylation, events associated with transcription initiation and elongation,
respectively [13,14]. Subsequently, advancedRNAsequencing technolo-
gies have revealed that c-Myc globally ampliﬁes transcription of the
majority of RNA pol II genes [15,16]. In addition to increasing mRNA
transcription, c-Myc has been found to inﬂuence mRNA translation by
promoting RNA polymerase I and III-dependent transcription, thus up-
regulating rRNA (ribosomal RNA) and tRNA (transfer RNA) production
[17–20].4. mRNA 7-methylguanosine cap
A key process during transcription of protein-encoding RNA pol II
transcripts, whether c-Myc-regulated or not, is the addition of the
“cap” structure to the initiating nucleotide [21,22] (Fig. 1). The cap con-
sists of 7-methylguanosine linked to theﬁrst transcribednucleotide by a
5′ to 5′ triphosphate bridge (abbreviated to m7G). The cap structure is
thought to be unique to the 5′ end of RNA pol II transcripts, selecting
them for speciﬁc handling and processing required for their ultimate
expression [23–25]. In mammals, the ﬁrst and second transcribed nu-
cleotides can also be O-2 methylated, forming part of the recognised
cap structure [26].
Three enzymic activities catalyse m7G formation, a triphosphatase,
guanylyltransferase and methyltransferase [26] (Fig. 2). RNA is syn-
thesised with a 5′ triphosphate, denoted ppp(5′)Np (where N is the
ﬁrst transcribed nucleotide). A triphosphatase removes the terminal
phosphate and a guanylyltransferase catalyses addition of an inverted
guanosine cap to create the cap intermediate, G(5′)ppp(5′)G. Amethyl-
transferase methylates the inverted guanosine cap on the N-7 position
to create “Cap 0”, denoted 7mG(5′)ppp(5′)Np. Methylation of the ﬁrstFig. 1. Diagram of the mRNA cap. The mRNA cap is 7-methylguanosine linked via a 5′ to 5′
nucleotides can also be methylated on the ribose 2-hydroxyl position creating Cap1 and Cap2,and second transcribed nucleotides on the O-2 position of the ribose
creates the structures known as Cap1 and Cap2, respectively.
Although the basic enzymic activities utilised to promote capping
are similar in all eukaryotes, the genomic arrangement of the capping
enzymes varies signiﬁcantly in different species [26]. Since this review
is concerned with the function of c-Myc in humans, we will focus on
the discussion of the mammalian capping enzymes. In mammals, the
triphosphatase and guanylyltransferase are contained on a single poly-
peptide, RNGTT (RNA guanylyltransferase and 5′ phosphatase) [27–29],
and the methyltransferase is contained in a separate enzyme, RNMT
(RNA guanine-7 methyltransferase) [29,30] (Fig. 2). RNMT is isolated
from mammalian cells in a complex with an activating subunit, RAM
(RNMT-activating mini-protein) [31,32]. The guanylyltransferase reac-
tion is reversible whereas N-7 methylation is not, thus N-7methylation
“locks-in” the cap structure. CMTR1 and CMTR2 methylate the ﬁrst and
second transcribed nucleotides, although not all transcripts receive this
modiﬁcation [33,34]. Furthermore, the precise mechanisms of function
of CMTR1 and CMTR2 are in the early days of characterisation and not
mentioned further here.
The cap methylation reaction is not readily reversible, however the
entire cap can be removed by a variety of “decapping enzymes”
[35–37]. mRNA is unstable without the cap and therefore decapping
either initiates degradation or is a later stage of the degradation process.
The decapping enzyme complexes can potentially act on all transcripts
but in vivo can exhibit speciﬁcity for certain transcripts. Furthermore,
various auxiliary proteins can increase decapping enzyme activity and
direct the decapping complexes towards speciﬁc transcripts, thus
facilitating cellular regulation of the process.
5. Capping and transcription
Not only does formation of the cap occur during transcription, it is
integral to the process. RNA is vulnerable to degradation during the
early stages of transcription and addition of the cap structure protects
RNA pol II transcripts from attack by exonucleases. Addition of the cap
thus passively permits transcripts to be synthesised [38,39].
Capping occurs shortly after transcription initiation and is restricted
to RNA pol II transcripts since the capping enzymes RNGTT and RNMT–
RAM are only recruited to this polymerase [40,41]. The RNA pol II large
subunit C-terminal domain (CTD) is a recruitment platform for enzymes
and factors which regulate transcription and modify RNA, including
the capping enzymes [12,42]. Recruitment of factors to the CTD is co-
ordinated by a series of phosphorylation events and other post-
translational modiﬁcations. RNGTT and RNMT–RAM are recruited at
the initial phases of transcription when the RNA polymerase II CTD is
phosphorylated on Serine-5 [43,44]. RNGTT is activated by interactiontriphosphate bridge to the ﬁrst transcribed nucleotide. The ﬁrst and second transcribed
respectively.
Fig. 2. mRNA cap synthesis. Nascent RNA is transcribed with a 5′ triphosphate, denoted ppp(5′)Np, where N is the ﬁrst transcribed nucleotide. RNGTT has triphosphatase and
guanylyltransferase activities and catalyses addition of the inverted guanosine cap to create, G(5′)ppp(5′)Np. RNMT is the cap methyltransferase which methylates the guanosine cap
on the N-7 position to create Cap 0 m7G(5′)ppp(5′)Np.
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transcription elongation factor hSPT5 [47].
6. mRNA cap function
The mechanism of capping can have a “pro-active” effect on
transcription. In yeast species, all three capping enzymes have been
demonstrated to inﬂuence transcription, some independent of enzymic
activity [40,41,48]. Recruitment of the capping enzymes has been dem-
onstrated to be integral to the switch from transcription initiation to
elongation [48,49]. In mammals, only RNGTT has been demonstrated
to promote transcription to date [50]. In vitro, RNGTTwas demonstrated
to relieve repression by NELF (negative elongation factor), indicating a
role for the capping enzyme in release of RNA pol II from pausing/
promoter clearance. It is not a forgone conclusion that RNMT–RAM
will be found to inﬂuence transcription in mammals. There are key dif-
ferences between yeast and mammals in the processes of transcription
initiation and elongation; release of polymerase from pausing is more
complex and heavily regulated in mammals. Furthermore, the capping
enzymes are conﬁgured differently in yeast and mammals [26]. In
yeast species, there are three distinct capping enzymes, whereas in
mammals the triphosphatase and guanylyltransferase are found on
the same peptide, RNGTT. The cap methyltransferase, RNMT, has an
activating subunit, RAM, in mammals which is not found in yeast [31].
In addition the mammalian cap methyltransferase has an N-terminal
domain which is required for efﬁcient recruitment to RNA pol II which
is not present in yeast species [44].
As described above, the cap is added to the transcripts shortly after
initiation and remains throughout its lifetime. The cap directs RNA pol
II transcripts to be processed quite distinctly from RNA pol I and III
transcripts. The cap structure mediates processing events ultimately re-
quired for translation, including, splicing, mRNA export, polyadenylation
and translation initiation [23–25]. Factors including CBC (cap binding
complex) and eIF4E (Eukaryotic initiation factor 4E) bind to the cap struc-
ture and recruit the proteins required for processing and translation initi-
ation.Many studies have found the cap or cap-binding protein complexes
to have gene-speciﬁc effects on RNA processing and translation [23–25].
Modern sequencing technologies are beginning to provide the experi-
mental means of determining the precise function of the cap genome-
wide. For example, which transcripts (and which exons) require methyl-
ation of the cap for splicing and which transcripts require methylation
of the cap for export? Since most gene expression processes are tightly
coupled, discerning direct from indirect effects of the cap in endogenous
gene expression is experimentally challenging. This problem is com-
pounded in mammalian systems by protein knock-down/knock-out
technologies requiring many hours or days to become effective. Precise
determination of the direct versus indirect effects of the cap on gene ex-
pression is likely to be improved by the development of speciﬁc inhibitors
of the capping enzymes, RNGTT and RNMT–RAM.
7. c-Myc regulates capping
In 2007, c-Mycwas found to promote formation of the cap structure,
thus synergistically promoting transcription and translation of RNA pol
II transcripts (Fig. 3) [14,51,52]. This was an unexpected ﬁnding sincecapping was widely regarded as a “house-keeping” event, evolved to
select RNA pol II transcripts for speciﬁc processing and handling. As
described earlier, capping and transcription aremechanistically coupled
processes and c-Myc promotes these processes by partially overlapping
mechanisms [14,51,52]. c-Myc binds proximal to promoters, most fre-
quently to conserved binding sites downstream of transcription initia-
tion sites [53–55]. c-Myc promotes TFIIH recruitment to DNA by direct
interaction with the kinase complex, and probably also by relaxing the
chromatin structure [13,14,56]. RNA pol II phosphorylation promotes
recruitment of the capping enzymes, RNGTT and RNMT, and activation
of RNGTT [12,42]. For the transcripts investigated, this correlates with
increased capping, translation and protein expression [14].
The mechanism of c-Myc-dependent cap formation is also de-
pendent on upregulation of the enzyme, SAHH (S-adenosyl homocyste-
ine hydrolase) [52]. Methylation reactions utilise the methyl donor,
S-adenosyl methionine (SAM) and produce the bi-product S-adenosyl
homocysteine (SAH) [57]. SAH inhibits methylation reactions by com-
peting with SAM for the active site. c-Myc-dependent cap formation
was found to be dependent on upregulation of SAHHwhich hydrolyses
SAH to the neutral products homocysteine and adenosine. c-Myc-
dependent cap methylation is particularly sensitive to SAHH levels; in-
hibition of c-Myc-dependent SAHH upregulation to basal levels reduces
c-Myc dependent gene expression, cell proliferation and cell transfor-
mation [52]. Manymethyltransferase have been found to be dependent
on SAHH levels, including the Adenosine N-6 methyltransferase [58].
Since c-Myc signiﬁcantly increases SAHH expression it seems likely
that c-Myc will inﬂuence other RNA methylation events.
Which step in cap formation does c-Myc regulate; addition of the
guanosine cap catalysed by RNGTT, N-7 methylation of the guanosine
cap catalysed by RNMT, or both? Since c-Myc increases RNA pol II phos-
phorylation, it could potentially increase recruitment of RNGTT and
RNMT, i.e. promote guanosine cap addition andmethylation of the gua-
nosine cap. We know that c-Myc increases the proportion of transcripts
with a 7-methylguanosine cap (m7G(5′)ppp(5′)Np), but currently we
do not know whether the transcripts without this structure have the
inverted guanosine cap added (G(5′)ppp(5′)N), or not (ppp(5′)N).
Although uncapped transcripts are unstable at the initial stages of tran-
scription, during transcription elongation they rapidly become coated in
proteins and gain secondary structure which probably stabilises the
transcript. The question ofwhether unmethylated transcripts have a gua-
nosine cap or not is important since some of the cap-binding proteins
have afﬁnity for the guanosine cap, albeit reduced [23–25]. Therefore
transcripts that have a guanosine cap are probably more translation-
competent than those without. In yeast, incompletely capped transcripts
have also been observed, particularly under conditions of nutritional
stress [59,60]. Furthermore, incompletely capped transcripts have also re-
cently been observed in other mammalian systems [61].
We do not understand why certain transcripts are more receptive
for c-Myc-dependent capping than others. This is likely to be governed
by features of the gene or transcript. For example, certain chromatin
conﬁgurations may result in more access of RNA pol II to the capping
enzymes, or faster transcription rates may reduce the time the capping
enzymes have access to the transcript. Alternatively, 5′ untranslated re-
gions of transcripts which hold signiﬁcant secondary structure may
have less access to the capping enzymes. Whole genome analysis of
Fig. 3. c-Myc regulated mRNA cap synthesis. c-Myc-Max binds proximal to transcription initiation sites, promotes TFIIH recruitment and RNA pol II phosphorylation. RNGTT and RNMT–
RAM are recruited to the phosphorylated C-terminal domain of RNA pol II, where they catalyse mRNA cap (m7G) synthesis. The methylation reaction uses the methyl donor, SAM
(s-adenosyl methionine), and produces the inhibitory bi-product SAH (s-adenosyl homocysteine). c-Myc upregulates SAHH (S-adenosyl homocysteine hydrolase) which catalyses hydrolysis
of SAH producing adenosine and homocysteine (HCY).
504 S. Dunn, V.H. Cowling / Biochimica et Biophysica Acta 1849 (2015) 501–505the recruitment of the capping enzymes may begin to distinguish
between these possibilities.
8. Do other transcription factors regulate capping?
Is c-Myc a special case in being a transcription factor which pro-
motes mRNA cap methylation? Probably not. The Myc proteins, c-Myc
and N-Myc both up regulate formation of the cap [14,51,52]. E2F1 is an-
other transcription factor which promotes formation of the cap in a
mechanism dependent on RNA pol II phosphorylation [51,62]. It
seems likely that any transcription factor which inﬂuences RNA pol II
phosphorylation will promote capping of a subset of transcripts. Fur-
thermore, since mRNA cap methylation is highly dependent on SAHH,
any signalling pathways that regulate SAHH expression or activity are
likely to inﬂuence mRNA cap methylation.
9. Targeting capping
Mechanisms which c-Myc utilises to promote cell proliferation have
the potential to be targeted therapeutically to inhibit deregulated cell
proliferation in tumour cells [3]. The question of whether mRNA cap
synthesis should be investigated as a potential therapeutic target can
be addressed from both biological and practical perspectives.
From a biological perspective, the current published research sug-
gests that capping should be considered as a therapeutic target. Inhibi-
tion of SAHH speciﬁcally inhibits the proliferation of cells harbouring
deregulated c-Myc [52]. Furthermore, upregulating expression of
RNMT is sufﬁcient to transformmammary epithelial cells [63]. Although
abolishing capping is likely to be lethal in all mammalian cell lineages,
mild inhibition of cappingmay selectively target themost transcription-
ally active cancer cells. Most current cancer therapeutics target major
cellular pathways, which if abolished would result in cell lethality, but
when attenuated have selectivity for transformed cells.
From a practical perspective, mRNA cap synthesis is catalysed by en-
zymes, which have the potential to make good targets since they al-
ready bind to small molecules (ligands) in their active sites. RNMT
would appear to be a better potential target than RNGTT since the latter
has a highly charged active site, and is therefore likely to bind to
charged/polarmolecules, which are resistant to passage across the plas-
mamembrane. Compounds that inhibit the active site of RNMT are cur-
rently available, but lack speciﬁcity [52]. Although the vast majority of
inhibitors target enzyme active sites, protein–protein interactions are
being increasingly utilised as therapeutic targets. As described earlier,
RNMT exists in a heterodimer with an activating subunit RAM(RNMT-activating miniprotein) [31,32]. RAM activates RNMT six-fold
in vitro and disrupting the interaction between RNMT and RAM may
provide the possibility of reducing rather than annihilating the cellular
cap methyltransferase activity, thus limiting toxicity.
10. Conclusion and remarks
Much remains to be discovered about themechanism and biological
signiﬁcance of c-Myc-regulation ofmRNA cap synthesis. c-Myc is one of
the ﬁrst examples of a cellular signalling protein regulating mRNA cap
synthesis. Given the overlapping mechanisms of transcription and
capping, it seems likely that many transcriptional regulators will pro-
mote capping to some extent. It is also possible that other signalling
pathways will be found to regulate capping by regulating capping en-
zyme expression or activity.
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